CHRS - Coherus BioSciences Stock Is Soaring After-Hours - Here's Why | Benzinga
Coherus BioSciences, Inc. (NASDAQ: CHRS) shares are trading higher in Tuesday's after-hours session following the company's announcement of the U.S. Food and Drug Administration's (FDA) approval of UDENYCA ONBODY for pegfilgrastim-cbqv.
What To Know: The company announced the FDA approval after the close of the market on Tuesday. UDENYCA ONBODY is the company's on-body injector presentation of UDENYCA (pegfilgrastim-cbqv), a pegfilgrastim biosimilar administered the day after chemotherapy to reduce the ...